Destiny Pharma Share Discussion Threads

[malcolmmm] 02/12/2020 09:05

He's a man in the know . Good idea to follow suite imo

[supracat] 01/12/2020 21:24

He knows success is just around the corner. I wonder if his was the large purchase of 300k yesterday to bring him up over the 3% reporting threshold...??

[mikeh30] 01/12/2020 19:40

Very interesting he's bought a stake

[mikeh30] 01/12/2020 17:54

Another holdings RNS. Sir Nigel Rudd/lady Leslie Rudd

[gbjbaanb] 01/12/2020 14:29

I'm not sure, I expected a re-rating after the shared were issued and the EGM ended, but that should have been yesterday. I think we're stuck with this price for a while now, until some news or results come in.

[malcolmmm] 01/12/2020 08:54

cant buy online at the moment so perhaps a mark up

[supracat] 30/11/2020 21:05

Agree. Me too. Managed another 80k in the open offer as felt it was a good opportunity at these levels which prob won't come up again.

[malcolmmm] 30/11/2020 15:07

Topped up this morning as they look like they are on the move

[goblin99] 30/11/2020 14:55

Unicorn fund now holding 5%.

[edmonda] 27/11/2020 09:01

Indeed

Equity Dev adjusts forecasts for issue approval, Phase 3-ready NTCD M3 product, uptake of XF-73 once approved on removal of US competition

Their fair value of Destiny Pharma increases to £156.9m (262p/share).

Read full note here:

[t0pgrader] 27/11/2020 08:34

ED share price target increased to 262p due to GSK discontinuing their competitor product. Good news.

[mikeh30] 13/11/2020 09:53

WAAW starts 18th November so expect interest to build into this.You also can't discount news at any time from the AMR $billion fund especially after the acquisition:The Global Action Plan on Antimicrobial Resistance, WHO undertakes an annual quantitative and qualitative analysis of the clinical development pipeline of antibacterial treatments that target the WHO priority pathogens, TB and Clostridioides difficile

[supracat] 13/11/2020 08:21

Not a lot will happen until after the meeting end of Nov. I do suspect that they might announce all the ph2b patients signed up around then to meet FDA reqs. Then expect a significant re rate up over 100p again.

[malcolmmm] 12/11/2020 23:15

Thanks kipper1960, a great help

[kipper1960] 12/11/2020 18:10

shareholders' entitlement is 1 share for every 14 held on 10/11, at 0.65GBP each. Cut off date is 24/11. EGM on 26/11 to approve placing.

FWIW I think this this placing is holding back the share price at around 0.65 but after the EGM (26/11) will rerate quickly. 2 valuations were at around £2 per share - before the C Difficile acquisition - and after it Finncap ( DEST's broker) raised valuation to about £3. Obviously this will depend greatly on the results of the ph. 2B clinical trials for XF-73. Not sure on the timing of these, either Q420 or Q121

[malcolmmm] 12/11/2020 09:32

I bought some yesterday. Does anyone know the timetable of events, placing of the shares etc?

[goblin99] 12/11/2020 07:38

https://pubmed.ncbi.nlm.nih.gov/30093897/

[malcolmmm] 11/11/2020 10:14

Received the above email from equity yesterday. Very interesting.

[edmonda] 10/11/2020 13:56

Another view from analyst Dr Andy Smith at Equity Development: 'a transformational deal for Destiny that would catapult its pipeline into late stage development / enhance preventative microbiome-promoting therapies'

New research note today sees jump in fair value on completion to 224p/share, read it here:

[t0pgrader] 10/11/2020 12:34

FC's share price target of 301p assumes (1) a 53% probability of XF-73 reaching market and 60% for NTCD-M3 and (2) Zero milestone receipts from licencees.

Since FDA approval and therefore value is largely binary I would prefer to say the upside potential valuation is at least 550p plus whatever milestone payments you think appropriate and excl the cash being raised.

[goblin99] 10/11/2020 11:52

To do with tax relief in essence. If you hold in an ISA already, I do not believe it makes much difference.https://www.pruadviser.co.uk/knowledge-literature/knowledge-library/eis-vct-seis/#

[supracat] 10/11/2020 11:32

That's what I thought but also mention of EIS and VCT shares too so I got a bit confused about it all... will wait to get all the paperwork through.

[goblin99] 10/11/2020 11:25

Is it not a case of offer to existing holders at the open offer price - 65p?

[supracat] 10/11/2020 11:04

Sounds really positive. Not entirely sure why share price is getting hammered today though??. Am waiting to see the terms of the offer for existing shareholders before buying more in open mkt. Destiny feels like a £200m+ company already and still can't believe it's only £30m!!!

[wh1spa] 10/11/2020 10:46

They value the latest acquisition at 57p on its own.